Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)

NCT05555862 is registered in ClinicalTrials.gov with Frantz Viral Therapeutics, LLC as lead sponsor.

NCT NCT05555862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
Lead sponsor
Frantz Viral Therapeutics, LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 10, 2023
Completion date
December 31, 2026
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ain 2/3, anal dysplasia, anal high grade squamous intraepithelial lesion, anal precancerous condition, hpv disease, hpv infection